title: Hemostatic complications in leukemic patients.
abstract: With clinical vigilance and laboratory tests of platelet and coagulation factor function, the clinician can promptly recognize and treat hemostatic disorders in leukemic patients. For example, laboratory values are strikingly abnormal in disseminated intravascular coagulation. Prompt neutralization of the underlying cause of the coagulopathy is essential. Platelet and coagulation factors may have to be replaced if the disorder is severe. Diffuse petechiae, purpura, mucous membrane bleeding, and hemorrhage around venipuncture or infusion sites indicate thrombocytopenia. Vigorous platelet replacement is necessary to prevent massive intracranial of gastrointestinal hemorrhage. Platelet dysfunction may cause spontaneous bleeding or immediate or delayed hemorrhage after surgery. The abnormality is often evident in peripheral blood smear or indicated by bleeding time or aggregation studies. If possible, sufficient autologous platelets should be infused to return the bleeding time to normal. Immune thrombocytopenic purpura may be easy to diagnose when the reduction in the circulating platelet count is compared with the normal number of marrow megakaryocytes. But attempts to increase platelet count by platelet transfusions may be frustrating. Treatment involves high doses of corticosteroids, followed by splenectomy if necessary.
mesh_terms: D001778:Blood Coagulation Disorders / Q000209:etiology*; D001791:Blood Platelet Disorders / Q000175:diagnosis / Q000209:etiology; D004211:Disseminated Intravascular Coagulation / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D006801:Humans; D007938:Leukemia / Q000150:complications*; D011696:Purpura, Thrombocytopenic / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D013921:Thrombocytopenia / Q000175:diagnosis / Q000209:etiology / Q000628:therapy